hotspot -WSS

hotspot

author：entertainment 2025-10-01 22:48:54 - browse：32416

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — A newly approved Alzheimer’s drug made by Eisai and Biogen, called Leqembi, aims to clear out amyloid plaques in patients’ brains. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

WASHINGTON — Medicare on Monday proposed ending restrictions on how many PET scans patients can receive to detect amyloid plaques in their brains, which will offer physicians more options as they treat patients with a new drug to slow the progression of dementia.

The agency that oversees Medicare had previously restricted coverage to a single scan for patients who participated in clinical studies. Advocates had warned that could cause issues related to a new class of Alzheimer’s drugs designed to clear those plaques.

“We know there is significant interest in the medical community about new treatments that may be effective in slowing the development of Alzheimer’s disease. PET scans are an important part of diagnosis and treatment of Alzheimer’s disease,” Centers for Medicare and Medicaid Administrator Chiquita Brooks-LaSure said in a written statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： How to fix the rural physician shortage in the U.S.

WSS

How to fix the rural physician shortage in the U.S.

Pregnant women don't need prenatal multivitamins, study concludes

Kenai launches with $82 million for Parkinson’s stem cell therapy

A new approach to psychiatric drug development

Change Healthcare cyberattack outage could last weeks

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

entertainment

hotspot

hotspot

How to save PrEP access — and even expand it

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Supreme Court strikes down use of affirmative action

Scientists unlock the key to scar

The high cost of giving birth even with insurance

Scientists unlock the key to scar

Hepatitis C has a cure — but many Americans still lack access to it

The untold story of TV’s first prescription drug ad

The high cost of giving birth even with insurance

RSV vaccines may be linked to small increased risk of developing GBS

focus

FogPharma raises $145 million in rare Series E round

Longer MASH drug regimen improved liver, Akero study finds

State of the Union pitch: Bigger Medicare drug price negotiations

For AI in health care standards, federal regulators join with industry group

Readout Newsletter: BridgeBio, Akero, and human embryo models

Biden's 'march

knowledge

Wikipedia

Wikipedia

focus